Current Report Filing (8-k)
19 12월 2020 - 4:23AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 18, 2020
NUTRALIFE
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
|
Florida
|
|
000-55144
|
|
46-1482900
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
6601
Lyons Road, Suite L-6, Coconut Creek, FL 33073
(Address
of Principal Executive Office) (Zip Code)
(888)
509-8901
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
7.01 Regulation FD Disclosure
On
December 18, 2020, NutraLife BioSciences, Inc. (the “Company”) issued a press release providing a Company update.
A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained
in the websites referenced in the press release are not a part of this Current Report on Form 8-K.
The
information included in Item 7.01 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The
information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current
Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
NUTRALIFE
BIOSCIENCES, INC.
|
|
|
|
|
|
Date: December 18,
2020
|
By:
|
/s/
Edgar Ward
|
|
|
|
Edgar
Ward
Chief
Executive Officer
|
NutraLife Biosciences (CE) (USOTC:NLBS)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
NutraLife Biosciences (CE) (USOTC:NLBS)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
